DNA Gyrase Subunit B (EC 5.99.1.3) Market to Reach $3.6 Billion by 2035

DNA gyrase subunit B (EC 5.99.1.3) market was valued at $1.6 billion in 2025 and is projected to reach $3.6 billion by 2035, growing at a CAGR of 8.8% during the forecast period (2026-2035). The increasing prevalence of antimicrobial resistance is a primary factor supporting the growth of the DNA gyrase subunit B market. According to the Centers for Disease Control and Prevention, more than 2.8 million antimicrobial-resistant infections occur annually in the United States, resulting in over 35,000 deaths, reflecting the significant clinical burden associated with resistant pathogens. In parallel, the World Health Organization reported that at least 1.27 million deaths were directly attributed to antimicrobial resistance, with nearly 5 million deaths associated with such infections globally. The continued rise in resistance across key pathogens, including Klebsiella pneumoniae and other gram-negative bacteria, is limiting the effectiveness of existing antibiotic classes. This has created a clear therapeutic gap, increasing the need for drugs with novel mechanisms of action such as DNA gyrase subunit B inhibitors. These agents offer a differentiated pathway to overcome resistance mechanisms associated with traditional gyrase-targeting antibiotics. The growing clinical urgency to address treatment failure in severe infections is therefore accelerating the demand for innovative antibacterial therapies within this segment.

Browse the full report description of “DNA Gyrase Subunit B (EC 5.99.1.3) Market Size, Share and Trend Analysis Report, By Type (GYR-12, DS-2969, VXC-100, VT-12008911, and Others), By Application (Bacterial Infections, Clostridium Diffclie Infections, Klebsiella Pneumoniae Infections, and Others), Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/dna-gyrase-subunit-b-ec-59913-market

The trend is further reinforced by increasing resistance rates observed across multiple regions and healthcare settings. Data from the World Health Organization indicates that approximately one in six bacterial infections were resistant to antibiotics in 2023, with resistance rising in more than 40% of pathogen drug combinations between 2018 and 2023. In addition, surveillance data from the Centers for Disease Control and Prevention shows that hospital-acquired resistant infections increased by nearly 20% during recent years, highlighting persistent pressure on healthcare systems. These trends are directly influencing pharmaceutical research priorities, with greater emphasis on targeting validated bacterial enzymes such as DNA gyrase subunit B. The rising incidence of difficult-to-treat infections, combined with limited efficacy of existing therapies, is encouraging investment in next-generation antibacterial agents. As a result, the development and clinical advancement of gyrase B inhibitors are gaining momentum, positioning this segment as a critical area within the anti-infective drug landscape.

Innovation Leaders Transforming the DNA Gyrase Subunit B (EC 5.99.1.3) Market

The key players in the DNA gyrase subunit B (EC 5.99.1.3) market include Daiichi Sankyo Company, Limited , Vertex Pharmaceuticals Incorporated , Pfizer Inc., Merck & Co., Inc. , Shionogi & Co., Ltd. among others. These companies are advancing innovation in antibacterial drug development through the design of selective DNA gyrase subunit B inhibitors, enhanced molecular targeting approaches, and optimized compound efficacy, enabling effective treatment of resistant bacterial infections while addressing limitations of existing antibiotic classes and supporting the growing clinical need for next-generation anti-infective therapies.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Daiichi Sankyo Company, Limited , Vertex Pharmaceuticals Incorporated , Pfizer Inc., Merck & Co., Inc. , Shionogi & Co., Ltd. among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Report Segment

By Type

• GYR-12
• DS-2969
• VXC-100
• VT-12008911
• Others

By Application

• Bacterial Infections
• Clostridium Diffclie Infections
• Klebsiella Pneumoniae Infections
• Others

Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/dna-gyrase-subunit-b-ec-59913-market